Standard Family Office’s Alexion Pharmaceuticals ALXN Stock Holding History

Standard Family Office’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12	Closed	-$2K	–	561
2021 Q2	$2K	Hold	12	–	–	﹤0.01%	457
2021 Q1	$2K	Hold	12	–	–	﹤0.01%	486
2020 Q4	$2K	Buy	+12	New	+$1.54K	﹤0.01%	528

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Standard Family Office's ALXN Position: Q3 2021 in Review

Standard Family Office sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 12 shares — an estimated $2K sold.

Standard Family Office first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $2K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Standard Family Office reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Standard Family Office sold 12 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2K.
Standard Family Office first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Standard Family Office's Alexion Pharmaceuticals position peaked at $2K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Standard Family Office's 13F filing for Q3 2021, filed 15 Nov 2021.